This is a summary of the European public assessment report (EPAR) for Rasagiline Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Rasagiline Mylan. For practical information about using Rasagiline Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Rasagiline Mylan is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
Therapeutic Area (MeSH)
ATC Code
N04BD02
ATC Item
rasagiline
Pharmacotherapeutic Group
Anti-Parkinson drugs
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| rasagiline tartrate | N/A | Rasagiline Tartrate |
EMA Name
Rasagiline Mylan
Medicine Name
Rasagiline Mylan
Aliases
N/ANo risk management plan link.
